Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2017 53 280 M
EBIT 2017 18 459 M
Net income 2017 11 591 M
Debt 2017 8 928 M
Yield 2017 3,52%
Sales 2018 56 085 M
EBIT 2018 19 831 M
Net income 2018 12 675 M
Debt 2018 3 047 M
Yield 2018 3,74%
P/E ratio 2017 18,08
P/E ratio 2018 16,76
EV / Sales2017 4,15x
EV / Sales2018 3,84x
Capitalization 212 251 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
02/27Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
02/24 ROCHE : Presolicitation Notice - 1 year service & support contract for two Roche..
02/23 ROCHE : European Commission conditionally approves Roches cancer drug Alecensa
02/23 ROCHE : You 'cannot hang on to' breast cancer drug, high court tells roche
02/22 FOUNDATION MEDICINE : reports 4Q loss
02/22 FOUNDATION MEDICINE, INC. : Results of Operations and Financial Condition, Finan..
02/22 ROCHE : TAC Calls for Roche to Drop Price of Cancer Drug
02/22 CHUGAI PHARMACEUTICAL : ALK Inhibitor 'Alecensa' Approved in the EUAlecensa is A..
02/22 ROCHE : Registration closing soon for 11th annual Paediatric Clinical Trials sho..
02/21 ROCHE : Enters Hematology Market with Integrated Analyzer
02/21 ROCHE : receives EU approval of Alecensa (alectinib) for people with previously ..
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 279  CHF
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.210 192
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.11.86%182 412
More Results